LAG3 and neoplasm: Interactions between lymphocyte activation gene-3 (LAG-3 or CD223), T-cell immunoglobulin, and mucin domain-containing-3 (TIM-3), and their various ligands (e.g., Galectin-9, HMGB1, PS, and CD66a) diminish anti-tumor immunity through mechanisms such as inducing CD8+ T cell death and exhaustion [44,45].